| Name | Title | Contact Details |
|---|
Located in Nashville, TN, Paladin capital is a premier leader in business acquisition, and ownership transfer, via Employee Stock Ownership Plans (ESOP). Paladins mission is to provide employee ownership and retirement benefits to to the employees of the sellers company while providing private business owners a meaningful exit strategy that preserves their business legacy.
Unified Door & Hardware Group is a prominent distributor and service provider of commercial doors, hardware, and building specialties, located in Pennsauken, New Jersey. Established in 2013 from the merger of Commercial Hardware and TruFit, the company operates 31 locations nationwide and employs around 1,000 people, generating $92 million in revenue. In September 2024, it was acquired by Foundation Building Materials. The company offers a wide range of products and services across various construction divisions. This includes commercial doors and hardware, building specialties like bathroom partitions and fire protection, and access control systems. Unified Door & Hardware Group also provides custom fabrication, project management, professional engineering services, and installation for both new construction and aftermarket projects. They cater to diverse sectors such as healthcare, hospitality, government, and retail, working closely with contractors, developers, and building owners. Their extensive industry experience and commitment to personalized service set them apart in the market.
The WSAVA represents more than 200,000 veterinarians worldwide through its 110 member associations and works to enhance standards of clinical care for companion animals. Its core activities include the development of WSAVA Global Guidelines in key areas of companion animal veterinary practice and lobbying on important issues affecting companion animal care worldwide.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.